Lilly ED drug proves promising in small MD study; Merck touts new sleep-drug data; Cuba creates biotech 'conglomerate';

Conversations on Twitter :

 @FierceBiotech: New feature: 23andMe sets stage for stronger ties with pharma. Editor's Corner | Follow @FierceBiotech

 @JohnCFierce:  So rida goes down in flames in europe as well. Merck pulls app. More | Follow @JohnCFierce

 @RyanMFierce: Monkeys lost 10% of their body weight on Amgen's experimental antibody in 11-week study. News | Follow @RyanMFierce

> In a small study, Eli Lilly's ($LLY) Cialis proved promising for Becker muscular dystrophy. And investigators say the drug holds promise for Duchenne muscular dystrophy as well. Story

> New data for Merck's ($MRK) suvorexant demonstrated that the drug marginally improved sleep times for patients. Merck is hoping that the sleep drug can penetrate a dwindling market with a better safety profile. Story

> Fort Collins, CO-based VetDC has raised $1.5 million in private financing to advance VDC-1101 towards veterinary approval in canine lymphoma. Release

> Cuba has banded 38 state-owned biotech and pharma companies into a conglomerate, hoping to accelerate the development of the industry in an economic reform drive. Story

Pharma News

@FiercePharma: J&J won't enforce its Prezista patent in Africa, provided generics makers sell quality copies. Article | Follow @FiercePharma

> AbbVie to ring in 2013 as an independent drugmaker. Story

> AZ wins Chinese nod for lagging bloodthinner Brilinta. News

> FDA's Sklamberg promoted to director of CDER's Office of Compliance. Item

> J&J opens HIV fighter Prezista to copycats in poor countries. Article

Medical Device News

 @FierceMedDev: Roche Dx scores top marks for glucose meter satisfaction. More | Follow @FierceMedDev

@MarkHFierce: In 2012, medical device and Dx investment in China kicked into overdrive. Find out how, and why. Editor's Corner | Follow @MarkHFierce

 @DamianFierce: We've talked a lot about M&A targets in devices, but what about Sunshine Heart? C-Pulse could be worth $2.5B. News | Follow @DamianFierce

> Board approves Abbott split, effective Jan. 1, 2013. Report

> Bracco launches Class I recall of pre-filled syringes over stroke risk. Story

Pharma Manufacturing News

> Bracco Diagnostics recalls angiography drug over particulates. Story

> Eli Lilly CEO endorses anti-counterfeiting campaign in China. Report

> Capsugel gets organic designation for European products. News

Vaccines News

> Virus found in dogs may fuel new vaccines. Report

> CureVac, German scientists take aim at faster flu vaccine. Article

> Danish-made TB vaccine sickens Romanian children. Item

> Selecta inks $900M immunotherapy deal with Sanofi. Story

And Finally… Investigators say that homicides tend to spread much like a virus does, creating an infectious disease pattern that could help police fight crime. Story

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.